Navigation Links
Roche confirms Tamiflu production talks in US

Swiss pharmaceutical giant Roche confirmed that it is in talks with 15 companies in the U.S. about stepping up the production of Tamiflu, the bird-flu drug//.

The partnership would dramatically increase the world's supply of Tamiflu as countries are stockpiling the drug in preparation for a possible bird flu pandemic.

The Basel-based firm confirmed on Thursday that it was in talks with Teva Pharmaceuticals and Mylan Laboratories, but declined to provide the names of any other companies.

"Roche is in advanced discussions with potential partners that can help enhance its supply chain and add capacity for certain specialized steps in the manufacturing of Tamiflu," the company said in a statement.

It added that it was "moving ahead as planned with third-party discussions" and would publish further details at a later date.

Increasing supply

The statement came after US Senator Charles Schumer said, "the purpose is not to break the patent on Tamiflu, but rather to meet an emergency need for quantities of this drug that Roche itself simply cannot do alone."

"Roche has made the right decision," Schumer said. "Instead of closely holding their patent rights and production techniques, in the face of a global health risk, they've moved swiftly to partner with multiple companies to dramatically increase production of this potentially life-saving drug."

The drug is in short supply in many parts of the world because of the fear of bird flu, a form of influenza that has been contracted by humans who have had close contact with infected poultry.

Tamiflu is one of four drugs known to work against influenza. It does not cure the virus but can reduce the severity of infection. Doctors believe it may help control a pandemic of H5N1 avian influenza, although evidence suggests it may be less effective than it is against seasonal influenza.

The drug, invented by California-based Gilead Sciences Inc., is in short supply. Countries are seeking to stockpile it but all are many million doses short of what would be needed to treat a pandemic of any sort of influenza, if there is one.

Last month Roche said Indonesia, Thailand and the Philippines were free to begin making their own versions of the drug because it does not have patent protection in these countries.
'"/>




Related medicine news :

1. FDA Imposes New Restrictions On Roches Accutane
2. Roche offers HIV drug expertise to poor nations
3. Roche Commits More Antiviral Pills To Asia For Bird Flu
4. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
5. Roche Rolls Out Lung Cancer Drug In India
6. New Lung Cancer Drug Launched By Roche Pharmaceutical
7. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
8. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer
9. NICE Gives the Final ‘NO’ to Roche’s Tarcva
10. SARS research confirms link to animals
11. Irritable bowel syndrome associated with food intake, confirms blood test
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... 28, 2017 , ... Rob Lowe is a popular actor that has been ... to an educational purpose as the host of the “Informed” series. The program focuses ... recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is an ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying ... will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive ... executive resume and wondering if it’s as ready as you are for a new ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
Breaking Medicine Technology: